A Phase 3 interventional study of Abatacept and Placebo in Active Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 10 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-18.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 42nd largest by enrollment, is one of 6 that started in 2007, is one of 26 in phase 3, and was the 15th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Montpellier · Sites in France, Monaco
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 27 · Phase 4 16
First in 2000; this study’s year is marked. 6 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 119 across the 63 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 63 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb: 4 open now, 8 under way, 2 of them phase 3. Of 82 finished, 31 (38%) have results posted.
Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, this one is the 46th largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2007, is one of 22 in phase 3, and was the 17th registered.
Bristol-Myers Squibb’s Arthritis, Rheumatoid studies by the year they started, since 2000.
1 of the studies testing abatacept in Arthritis, Rheumatoid that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, from their registry updates:
Among Bristol-Myers Squibb’s 92 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The only trial in participants who are methotrexate-inadequate responders and have active Rheumatoid Arthritis, in which gadolinium-enhanced Magnetic Resonance Imaging; Bone Mineral Density; and biochemical markers of bone, cartilage, and synovial tissue metabolism are used to evaluate early effects (4 months) of Abatacept on inflammation/structural damage. Study will provide valuable mechanism-of-action information on how Abatacept exerts its effects (including on bone) through new techniques.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Abatacept
Drug: Placebo
Vials (250 mg/vial), intravenous (IV), 10 mg/kg, monthly infusion , 12 months of treatment
Also known as: (BMS-188667), Orencia
Intravenous (IV) bags, IV, 0 mg, monthly infusion, 12 months of treatment
Double-blind Period: Mean Synovitis Scores at Baseline As Measured by the Rheumatoid Arthritis Clinical Trials 6 (OMERACT 6) Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS)
Wrist synovitis was assessed by postgadolinium MRI enhancement according to OMERACT 6 RAMRIS in 3 wrist regions: distal radioulnar, radiocarpal, and intercarpal and carpometacarpal joints. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3\*3 wrist regions), indicating most severe damage. Change in synovitis = Follow-up synovitis score - baseline score.
Time frame: At baseline
Double-blind Period: Mean Change From Baseline in OMERACT 6 Wrist Synovitis Score: Planned Analysis Using Non-Parametric ANCOVA
Wrist synovitis was assessed by postgadolinium MRI enhancement according to OMERACT 6 RAMRIS in 3 wrist regions: distal radioulnar, radiocarpal, and intercarpal and carpometacarpal joints. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3\*3 wrist regions), indicating most severe damage. Change in synovitis=Follow-up synovitis score-baseline score.
Time frame: Baseline to Day 113
Double-blind Period: Mean Change From Baseline in OMERACT 6 Wrist Synovitis Score: Post Hoc Sensitivity Analysis Using Parametric ANCOVA Analysis
Wrist synovitis was assessed by postgadolinium MRI enhancement according to OMERACT 6 RAMRIS in 3 wrist regions: distal radioulnar, radiocarpal, and intercarpal and carpometacarpal joints. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3\*3 wrist regions), indicating most severe damage. Change in synovitis score=Follow-up synovitis score-baseline synovitis score.
Time frame: Baseline to Day 113
Double-blind Period: Baseline Mean Erosion OMERACT 6 Scores
Bone erosion assessed at a total of 23 anatomic locations: 15 in 1 wrist and 8 in the hand of the same side. Each site is scored in 1.0 increments from 0 (no damage) to 10 (severe damage) according to erosion of the original articular bone (each unit=10% loss of articular bone). The total erosion score for the hands/wrists is the sum of the individual scores for each location. Thus the maximum score achievable per hand/wrist is 230. Increasing score=greater severity.
Time frame: At baseline
Double-blind Period: Adjusted Mean Change From Baseline in Erosion OMERACT 6 Scores
Bone erosion assessed at 23 anatomic locations: 15 in 1 wrist and 8 in attached hand. Each site is scored in 1.0 increments from 0 (no damage) to 10 (severe damage), indicating erosion (each unit=10% bone loss) of original articular bone. Total erosion score for hands/wrists is sum of the individual scores for each location. Thus the maximum score per hand/wrist is 230. Increasing score=greater severity. Adjusted change from baseline in erosion score=mean score at Day 113-mean erosion score at baseline. Adjustment based on ANCOVA model with treatment=factor and baseline value=covariate.
Time frame: Baseline to Day 113
Double-blind Period: Baseline Mean Osteitis OMERACT 6 Scores
Osteitis assessed at a total of 23 anatomic locations: 15 in 1 wrist and 8 in the hand of the same side. Each site is scored in 1.0 increments from 0 to 3, indicating involvement of original articular bone. The total score for the hands/wrists is the sum of the individual scores for each location. Thus the maximum score achievable per hand/wrist is 23 (total number of anatomic locations) \* 3 (maximum per joint)=69. Minimum score=0, indicating normal. Increasing score=greater severity.
Time frame: At baseline
Double-blind Period: Adjusted Mean Change From Baseline in Osteitis OMERACT 6 Scores
Osteitis assessed at 23 anatomic locations: 15 in 1 wrist and 8 in attached. Each site scored in 1.0 increments, indicating involvement of original articular bone (0=none to 3=severe). Total score for hands/wrists is sum of scores for each location. Maximum score per hand/wrist is 23 (total anatomic locations)\*3 (maximum score per joint)=69. Minimum score=0(normal). Increasing score=greater severity. Adjusted mean change from baseline in osteitis score=mean score at Day 113-mean score at baseline. Adjustment based on ANCOVA model with treatment=factor and baseline value=covariate.
Time frame: Baseline to Day 113
Double-blind Period: Number of Participants With Newly Involved Joints in Bone Erosion, Edema/Osteitis, and Synovitis
Bone erosion and osteitis were assessed at a total of 23 anatomic locations according to erosion (for bone erosion) or involvement (for osteitis) of the original articular bone. Synovitis assessed as above-normal post-gadolinium enhancement in 3 wrist regions: distal radioulnar joint, radiocarpal joint, and intercarpal and carpometacarpal joints.
Time frame: Baseline to Day 113
Double-blind Period: Baseline Mean RAMRIS Scores
RAMRIS score is the sum of its core components: Synovitis Score, Osteitis Score, and Erosion Score. Synovitis scored from 0 (normal) to 9 (maximum distension of synovial cavity). Osteitis scored 0 (normal) to 69 (maximum articular bone involvement). Erosion scored from 0 (normal) to 230 (maximum erosion of articular bone). RAMRIS=Synovial Score + Osteitis Score + Erosion Score. Minimum RAMRIS score=0 (normal), maximum RAMRIS score=308 (severe structural damage). For Synovial Score, Osteitis Score, Erosion Score, and RAMRIS score, increasing number=increasing severity.
Time frame: Baseline
Double-blind Period: Adjusted Mean Change From Baseline in RAMRIS Scores
RAMRIS Score=sum of core components: Synovitis (S), Osteitis (O), and Erosion (E) Scores. S scored 0 (none) to 9 (maximum distension of synovial cavity); O scored 0 (none) to 69 (maximum articular bone involvement); E scored 0 (none) to 230 (maximum erosion of articular bone). RAMRIS=S+O+E Scores. RAMRIS minimum score=0 (normal), maximum=308 (severe structural damage). Adjusted change from baseline in RAMRIS=mean RAMRIS at Day 113-mean RAMRIS at baseline. Adjustment based on ANCOVA model: treatment=factor, baseline value=covariate.
Time frame: Baseline to Day 113
Double-blind Period: Median Percent Change From Baseline in Systemic Markers of Bone Formation: Osteocalcin and Serum Intact N-terminal Propeptide of Type I Procollagen (PINP)
PINP and osteocalcin are markers of bone formation. Osteocalcin is synthesized by osteoblasts and is associated with osteoblast synthetic activity. Osteoblasts secrete type 1 procollagen, and cleavage of large fragments from the carboxy and amino terminal ends result in formation of mature type 1 collagen and production of PINP fragments.
Time frame: Baseline to Days 15, 29, 57, 85, and 113
Double-blind Period: Median Percent Change From Baseline in Systemic Markers of Bone Destruction (Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen [CTX-I] and Serum Pyridinoline Cross-linked Telopeptide Domain of Type I Collagen [ICTP])
CTX-I and ICTP are biochemical markers of bone resorption or bone degradation
Time frame: Baseline to Days 15, 29, 57, 85, and 113
Double-blind Period: Median Percent Change From Baseline in a Systemic Marker of Cartilage Degradation (Creatinine-corrected Urinary Carboxyterminal Crosslinking Telopeptide of Type II Collagen [UCTX2C])
Urinary CTX-II is a biochemical marker of type II collagen breakdown. In participants with early rheumatoid arthritis, increased levels of CTX-II can be predictive of rapid radiographic progression over periods of 1 to 5 years. These markers of cartilage destruction can predict progression of joint damage, independent of clinical and biologic indices of disease activity and baseline joint damage.
Time frame: Baseline to Days 15, 29, 57, 85, and 113
Double-blind Period: Median Percent Change From Baseline in Systemic Marker of Synovial Tissue Metabolism (Creatinine-corrected Urinary Glucosyl-Galactosyl-Pyridinoline [UGGPC])
Glucosyl-galactosyl-pyridinoline (Glc-Gal-PYD) is a specific biochemical marker reflecting the degradation of the synovial tissue membrane. It is a glycosylated derivative of the collagen crosslink pyridinoline, and it is present in significant amounts only in the synovial membrane; it is absent from bone and present in minutes amounts in cartilage and other soft tissues. Increased urinary levels of Glc-Gal-PYD have been found in early and long-standing rheumatoid arthritis, high levels being associated with rapid destruction.
Time frame: Baseline to Days 15, 29, 57, 85, and 113
Double-blind Period: Number of Participants With Death, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs, and AEs Leading to Discontinuation
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=possibly, probably, or certainly related to and of unknown relationship to study treatment.
Time frame: From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period
Double-blind Period: Number of Participants With AEs of Special Interest
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including serious, opportunistic, and all other infections; autoimmune disorders; neoplasms; acute infusional AEs (prespecified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (prespecified AEs occurring within 24 hours of start of infusion).
Time frame: From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period
Double-blind Period: Number of Participants With Infections/Infestations of Special Interest
Infections/Infestations of Special Interest are AEs and SAEs considered possibly, probably, or certainly related to study treatment, graded according to Common Terminology Criteria for Adverse Events Version 3.0 (Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death). AE=any new untoward medical occurrence or worsening of a preexisting medical condition which does not necessarily have a causal relationship with this treatment.
Time frame: From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period
Double-blind Period: Number of Participants With Acute Infusional AEs of Special Interest
Acute infusional AEs are AEs with onset during the first hour after the start of study drug infusion. An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. AEs considered possibly, probably, or certainly related to study treatment were graded according to Common Terminology Criteria for Adverse Events ,Version 3.0 (Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death).
Time frame: From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period
Double-blind Period: Number of Participants With Peri-infusional AEs of Special Interest
Peri-infusional AEs are AEs occurring during the first 24 hours after the start of study drug infusion. An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. AEs considered possibly, probably, or certainly related to study treatment were graded according to Common Terminology Criteria for Adverse Events, Version 3.0 (Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death).
Time frame: From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period
Double-blind Period: Number of Participants With Laboratory Test Results in Hematology Meeting the Criteria for Marked Abnormality
BL=baseline; LLN=lower limit of normal; ULN=upper limit of normal. Marked abnormality criteria: Hemoglobin: \>3 g/dL decrease from BL. Hematocrit: \<0.75\*BL. Erythrocytes: \<0.75\*BL. Platelets: \<0.67\*LLN/\>1.5\*ULN, or if BL \<LLN, use 0.5\*BL/\<100,000 mm\^3. Leukocytes: \<0.75\*LLN/\>1.25\*ULN, or if BL\<LLN, use \<0.8\*BL/\>ULN, or if BL\>ULN, use \>1.2\*BL/\<LLN. Neutrophils+bands: \<1.0\*10\^3 c/uL. Eosinophils: \>0.750\*10\^3 c/uL. Basophils: \> 400 mm\^3. Monocytes: \>2000 mm\^3. Lymphocytes: \<0.750\*10\^3 c/uL/\>7.50\*10\^3 c/uL.
Time frame: From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period
Double-blind Period: Number of Participants With Laboratory Test Results for Liver and Kidney Function Meeting Criteria for Marked Abnormality
ULN=upper limit of normal; BL=baseline. Marked abnormality criteria: Alkaline phosphatase: \>2\*ULN, or if BL\>ULN, use \>3\*BL; aspartate aminotransferase: \>3\*ULN, or if BL\>ULN,use \>4\*BL; alanine aminotransferase: \>3\*ULN, or if BL\>ULN, use \>4\*BL; G-Glutamyl transferase: \>2\*ULN, or if BL\>ULN, use \>3\*BL; Bilirubin: \>2\*ULN, or if BL\>ULN, use \>4\*BL; blood urea nitrogen: \>2\*BL; creatinine: \>1.5\*BL.
Time frame: From Day 1 to Day 113, and including up to 56 days post last dose of double-blind period, or start of first dose of open-label period
Double-blind Period: Number of Participants With Laboratory Test Results for Electrolytes Meeting the Criteria for Marked Abnormality
LLN=lower limit of normal; ULN=upper limit of normal; BL=baseline. Marked abnormality: Sodium: \<0.95\*LLN/\>1.05\*ULN,or if BL\<LLN, use 0.95\*BL or \>ULN,or if BL\>ULN, use\>1.05\*BL or \<LLN. Potassium: \<0.9\*LLN/\>1.1\* ULN,or if BL\<LLN, use 0.9\*BL or \>ULN, or if BL\>ULN, use\>1.1\*BL or \<LLN. Chloride: \<0.9\*LLN/\>1.1\*ULN, or if BL\<LLN, use 0.9\*BL or \>ULN, or if BL\>ULN, use\>1.1\*BL or \<LLN. Calcium: \<0.8\*LLN/\>1.2\*ULN, or if BL\<LLN, use 0.75\*BL or \>ULN, or if BL\>ULN, use\>1.25\*BL or \<LLN. Phosphorous: \<0.75\*LLN/\>1.25\*ULN, or if BL\<LLN, use 0.67\*BL or \>ULN, or if BL\>ULN, use\>1.33\*BL or \<LLN.
Time frame: From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period
Double-blind Period: Number of Participants With Laboratory Test Results in Other Chemistries and Urinalysis Meeting the Criteria for Marked Abnormality
LLN=lower limit of normal; ULN=upper limit of normal; BL-baseline. Marked abnormality c: serum glucose:\<65 mg/dL/\>220 mg/dL; fasting serum glucose: \<0.8\* LLN/\>1.5\* ULN, or if BL\<LLN, use 0.8\*BL or \>ULN, or if BL\>ULN, use \>2.0\*BL or \<LLN; total protein: \<0.9\*LLN/\>1.1\* ULN; albumin: \<0.9\*LLN,or if BL\<LLN, use \<0.75 BL; uric acid: \>1.5\* ULN, or if BL\>ULN, use \>2\*BL. Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, red blood cells, white blood cells):Use ≥2 when BL value missing or value ≥4,or when predose=0 or 0.5. Use ≥3 when predose=1. Use ≥4 when predose=2 or 3
Time frame: From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period
Double-blind Period:Number of Participants With Significantly Abnormal Changes in Vital Signs
Vital signs, which included blood pressure, heart rate, respiration, and temperature, were monitored predose and 1 hour after start of infusion. Changes in vital signs were determined to be significantly abnormal at the discretion of the investigator but were generally those that either exceeded, or failed to reach, normal parameters. Normal vital sign parameter ranges varied by site.
Time frame: Days 1, 15, 29, 57, 85, and 113
Double-blind Period: Number of Participants With Positive Antibodies to Abatacept by Electrochemiluminescence (ECL) Assay
On-Rx=on treatment; post-Rx=post treatment. ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction Category=reactivity against constant regions and/or hinge region of human IgG1.
Time frame: Day 1 to Day 113
| Milestone | Abatacept (ABA) + Methotrexate (MTX) | Placebo (PLA) + MTX |
|---|---|---|
| Started | 27 | 23 |
| Completed | 26 | 23 |
| Not completed | 1 | 0 |
| Withdrew: Participant no longer met study criteria | 1 | 0 |
Wrist synovitis was assessed by postgadolinium MRI enhancement according to OMERACT 6 RAMRIS in 3 wrist regions: distal radioulnar, radiocarpal, and intercarpal and carpometacarpal joints. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3\*3 wrist regions), indicating most severe damage. Change in synovitis = Follow-up synovitis score - baseline score.
| units on a scale | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Double-blind Period: Mean Synovitis Scores at Baseline As Measured by the Rheumatoid Arthritis Clinical Trials 6 (OMERACT 6) Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) | 4.48 ± 2.10 | 3.52 ± 2.43 |
Bone erosion assessed at a total of 23 anatomic locations: 15 in 1 wrist and 8 in the hand of the same side. Each site is scored in 1.0 increments from 0 (no damage) to 10 (severe damage) according to erosion of the original articular bone (each unit=10% loss of articular bone). The total erosion score for the hands/wrists is the sum of the individual scores for each location. Thus the maximum score achievable per hand/wrist is 230. Increasing score=greater severity.
| units on a scale | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Double-blind Period: Baseline Mean Erosion OMERACT 6 Scores | 12.60 ± 9.41 | 9.65 ± 10.11 |
Bone erosion assessed at 23 anatomic locations: 15 in 1 wrist and 8 in attached hand. Each site is scored in 1.0 increments from 0 (no damage) to 10 (severe damage), indicating erosion (each unit=10% bone loss) of original articular bone. Total erosion score for hands/wrists is sum of the individual scores for each location. Thus the maximum score per hand/wrist is 230. Increasing score=greater severity. Adjusted change from baseline in erosion score=mean score at Day 113-mean erosion score at baseline. Adjustment based on ANCOVA model with treatment=factor and baseline value=covariate.
| units on a scale | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Double-blind Period: Adjusted Mean Change From Baseline in Erosion OMERACT 6 Scores | 0.45 ± 0.43 | 0.95 ± 0.45 |
Wrist synovitis was assessed by postgadolinium MRI enhancement according to OMERACT 6 RAMRIS in 3 wrist regions: distal radioulnar, radiocarpal, and intercarpal and carpometacarpal joints. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3\*3 wrist regions), indicating most severe damage. Change in synovitis=Follow-up synovitis score-baseline score.
| units on a scale | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Double-blind Period: Mean Change From Baseline in OMERACT 6 Wrist Synovitis Score: Planned Analysis Using Non-Parametric ANCOVA | -0.44 ± 1.47 | 0.52 ± 1.38 |
Osteitis assessed at a total of 23 anatomic locations: 15 in 1 wrist and 8 in the hand of the same side. Each site is scored in 1.0 increments from 0 to 3, indicating involvement of original articular bone. The total score for the hands/wrists is the sum of the individual scores for each location. Thus the maximum score achievable per hand/wrist is 23 (total number of anatomic locations) \* 3 (maximum per joint)=69. Minimum score=0, indicating normal. Increasing score=greater severity.
| units on a scale | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Double-blind Period: Baseline Mean Osteitis OMERACT 6 Scores | 7.72 ± 7.04 | 8.00 ± 9.72 |
Osteitis assessed at 23 anatomic locations: 15 in 1 wrist and 8 in attached. Each site scored in 1.0 increments, indicating involvement of original articular bone (0=none to 3=severe). Total score for hands/wrists is sum of scores for each location. Maximum score per hand/wrist is 23 (total anatomic locations)\*3 (maximum score per joint)=69. Minimum score=0(normal). Increasing score=greater severity. Adjusted mean change from baseline in osteitis score=mean score at Day 113-mean score at baseline. Adjustment based on ANCOVA model with treatment=factor and baseline value=covariate.
| units on a scale | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Double-blind Period: Adjusted Mean Change From Baseline in Osteitis OMERACT 6 Scores | -1.94 ± 0.86 | 1.54 ± 0.90 |
Bone erosion and osteitis were assessed at a total of 23 anatomic locations according to erosion (for bone erosion) or involvement (for osteitis) of the original articular bone. Synovitis assessed as above-normal post-gadolinium enhancement in 3 wrist regions: distal radioulnar joint, radiocarpal joint, and intercarpal and carpometacarpal joints.
| participants | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| 0 newly involved joints (Bone Erosion) | 20 | 16 |
| ≥1 newly involved joints (Bone Erosion) | 5 | 7 |
| 0 newly involved joints (Edema/Osteitis) | 18 | 16 |
| ≥1 newly involved joints (Edema/Osteitis) | 7 | 7 |
| 0 newly involved joints (Synovitis) | 23 | 20 |
| ≥1 newly involved joints (Synovitis) | 2 | 3 |
RAMRIS score is the sum of its core components: Synovitis Score, Osteitis Score, and Erosion Score. Synovitis scored from 0 (normal) to 9 (maximum distension of synovial cavity). Osteitis scored 0 (normal) to 69 (maximum articular bone involvement). Erosion scored from 0 (normal) to 230 (maximum erosion of articular bone). RAMRIS=Synovial Score + Osteitis Score + Erosion Score. Minimum RAMRIS score=0 (normal), maximum RAMRIS score=308 (severe structural damage). For Synovial Score, Osteitis Score, Erosion Score, and RAMRIS score, increasing number=increasing severity.
| units on a scale | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Double-blind Period: Baseline Mean RAMRIS Scores | 24.80 ± 16.36 | 21.17 ± 20.45 |
RAMRIS Score=sum of core components: Synovitis (S), Osteitis (O), and Erosion (E) Scores. S scored 0 (none) to 9 (maximum distension of synovial cavity); O scored 0 (none) to 69 (maximum articular bone involvement); E scored 0 (none) to 230 (maximum erosion of articular bone). RAMRIS=S+O+E Scores. RAMRIS minimum score=0 (normal), maximum=308 (severe structural damage). Adjusted change from baseline in RAMRIS=mean RAMRIS at Day 113-mean RAMRIS at baseline. Adjustment based on ANCOVA model: treatment=factor, baseline value=covariate.
| units on a scale | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Double-blind Period: Adjusted Mean Change From Baseline in RAMRIS Scores | -1.82 ± 1.13 | 2.89 ± 1.18 |
PINP and osteocalcin are markers of bone formation. Osteocalcin is synthesized by osteoblasts and is associated with osteoblast synthetic activity. Osteoblasts secrete type 1 procollagen, and cleavage of large fragments from the carboxy and amino terminal ends result in formation of mature type 1 collagen and production of PINP fragments.
| percent change | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Day 15 osteocalcin (n=25, n=21) | 1.82 (-10.2 to 12.1) | 4.41 (-12.7 to 15.6) |
| Day 15 serum intact PINP (n=25, n=21) | 6.83 (-3.9 to 15.7) | 3.94 (-8.4 to 13.9) |
| Day 29 osteocalcin (n=26, n=21) | 2.43 (-8.8 to 18.2) | 12.14 (-10.1 to 19.2) |
| Day 29 serum intact PINP (n=26, n=21) | 11.62 (1.1 to 30.8) | -0.18 (-9.3 to 23.5) |
| Day 57 osteocalcin (n=25, n=21) | 4.02 (-7.7 to 25.4) | 10.53 (-3.7 to 22.8) |
| Day 57 serum intact PINP (n=25, n=21) | 3.68 (-8.1 to 43.1) | 12.18 (-6.7 to 20.2) |
| Day 85 osteocalcin (n=24, n=21) | 4.76 (-11.5 to 34.1) | 10.62 (-14.8 to 25.8) |
| Day 85 serum intact PINP (n=24, n=21) | 5.97 (-10.6 to 36.3) | -7.23 (-18.1 to 14.8) |
| Day 113 osteocalcin (n=24, n=21) | 3.18 (-8.2 to 11.8) | 7.87 (-8.3 to 19.0) |
| Day 113 serum intact PINP (n=24, n=21) | 2.98 (-19.8 to 28.8) | 4.75 (-16.1 to 24.7) |
CTX-I and ICTP are biochemical markers of bone resorption or bone degradation
| percent change | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Day 15 CTX-1 (n=25, n=21) | 1.65 (-23.0 to 13.0) | -6.37 (-24.6 to 23.2) |
| Day 15 ICTP (n=25, n=21) | -5.56 (-17.1 to 10.9) | 6.25 (-6.2 to 18.6) |
| Day 29 CTX-1 (n=26, n=21) | 0.48 (-28.2 to 32.2) | -0.72 (-21.2 to 18.6) |
| Day 29 ICTP (n=26, n=21) | -3.47 (-10.1 to 10.0) | 4.34 (-3.7 to 20.4) |
| Day 57 CTX-1 (n=25, n=21) | 15.13 (-17.9 to 26.5) | 7.02 (-11.4 to 16.7) |
| Day 57 ICTP (n=25, n=21) | -5.08 (-15.9 to 14.5) | 8.73 (-3.7 to 21.6) |
| Day 85 CTX-1 (n=24, n=21) | -6.94 (-35.9 to 21.5) | 15.65 (-18.9 to 40.8) |
| Day 85 ICTP (n=24, n=21) | -6.36 (-24.7 to 4.7) | 2.25 (-7.1 to 9.7) |
| Day 113 CTX-1 (n=24, n=21) | -7.23 (-36.4 to 21.3) | 0.00 (-27.5 to 35.3) |
| Day 113 ICTP (n=24, n=21) | -11.29 (-27.7 to 1.5) | 11.64 (-2.2 to 29.9) |
Urinary CTX-II is a biochemical marker of type II collagen breakdown. In participants with early rheumatoid arthritis, increased levels of CTX-II can be predictive of rapid radiographic progression over periods of 1 to 5 years. These markers of cartilage destruction can predict progression of joint damage, independent of clinical and biologic indices of disease activity and baseline joint damage.
| percent change | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Day 15 UCTX2C (n=24, n=21) | -8.51 (-35.9 to 13.7) | 5.14 (-11.7 to 8.4) |
| Day 29 UCTX2C (n=21, n=19) | -3.40 (-16.5 to 5.8) | 6.81 (-25.1 to 13.5) |
| Day 57 UCTX2C (n=23, n=19) | 0.24 (-50.0 to 25.0) | 5.43 (-12.3 to 24.8) |
| Day 85 UCTX2C (n=22, n=20) | -10.83 (-38.4 to 14.7) | 9.67 (-13.8 to 29.2) |
| Day 113 UCTX2C (n=22, n=20) | -18.49 (-46.9 to 54.2) | 9.86 (-22.4 to 46.3) |
Glucosyl-galactosyl-pyridinoline (Glc-Gal-PYD) is a specific biochemical marker reflecting the degradation of the synovial tissue membrane. It is a glycosylated derivative of the collagen crosslink pyridinoline, and it is present in significant amounts only in the synovial membrane; it is absent from bone and present in minutes amounts in cartilage and other soft tissues. Increased urinary levels of Glc-Gal-PYD have been found in early and long-standing rheumatoid arthritis, high levels being associated with rapid destruction.
| percent change | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Day 15 UGGPC (n=24, n=20) | 4.44 (-20.5 to 65.0) | -3.84 (-13.7 to 12.4) |
| Day 29 UGGPC (n=22, n=18) | -1.83 (-19.3 to 76.9) | -3.19 (-25.6 to 26.8) |
| Day 57 UGGPC (n=23, n=16) | 1.58 (-24.8 to 23.4) | 5.73 (-12.6 to 28.2) |
| Day 85 UGGPC (n=22, n=18) | 0.32 (-31.0 to 54.5) | 16.29 (-14.4 to 39.7) |
| Day 113 UGGPC (n=22, n=18) | -12.16 (-27.9 to 53.3) | -3.10 (-31.5 to 32.3) |
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=possibly, probably, or certainly related to and of unknown relationship to study treatment.
| participants | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Deaths | 0 | 0 |
| SAEs | 0 | 2 |
| Treatment-related SAEs | 0 | 0 |
| SAEs Leading to Discontinuation | 0 | 0 |
| AEs | 20 | 14 |
| Treatment-related AEs | 8 | 6 |
| AEs Leading to Discontinuation | 0 | 0 |
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including serious, opportunistic, and all other infections; autoimmune disorders; neoplasms; acute infusional AEs (prespecified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (prespecified AEs occurring within 24 hours of start of infusion).
| participants | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Infections | 1 | 0 |
| Malignancies | 0 | 0 |
| Autoimmune disorders | 0 | 0 |
| Acute infusional AEs | 0 | 4 |
| Peri-infusional AEs | 4 | 5 |
Infections/Infestations of Special Interest are AEs and SAEs considered possibly, probably, or certainly related to study treatment, graded according to Common Terminology Criteria for Adverse Events Version 3.0 (Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death). AE=any new untoward medical occurrence or worsening of a preexisting medical condition which does not necessarily have a causal relationship with this treatment.
| participants | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Double-blind Period: Number of Participants With Infections/Infestations of Special Interest | 1 | 0 |
Acute infusional AEs are AEs with onset during the first hour after the start of study drug infusion. An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. AEs considered possibly, probably, or certainly related to study treatment were graded according to Common Terminology Criteria for Adverse Events ,Version 3.0 (Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death).
| participants | Abatacept + Methotrexate | Placebo (PLA) + MTX |
|---|---|---|
| Grade 1 diarrhea | 0 | 1 |
| Grade 1 overdose | 0 | 1 |
| Grade 1 headache | 0 | 1 |
| Grade 1 flushing | 0 | 1 |
Peri-infusional AEs are AEs occurring during the first 24 hours after the start of study drug infusion. An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. AEs considered possibly, probably, or certainly related to study treatment were graded according to Common Terminology Criteria for Adverse Events, Version 3.0 (Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death).
| participants | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Grade 1 nausea | 3 | 0 |
| Grade 1 headache | 0 | 1 |
| Grade 2 headache | 1 | 1 |
| Grade 1 flushing | 0 | 2 |
| Grade 2 arthralgia | 0 | 1 |
| Grade 1 cough | 0 | 1 |
BL=baseline; LLN=lower limit of normal; ULN=upper limit of normal. Marked abnormality criteria: Hemoglobin: \>3 g/dL decrease from BL. Hematocrit: \<0.75\*BL. Erythrocytes: \<0.75\*BL. Platelets: \<0.67\*LLN/\>1.5\*ULN, or if BL \<LLN, use 0.5\*BL/\<100,000 mm\^3. Leukocytes: \<0.75\*LLN/\>1.25\*ULN, or if BL\<LLN, use \<0.8\*BL/\>ULN, or if BL\>ULN, use \>1.2\*BL/\<LLN. Neutrophils+bands: \<1.0\*10\^3 c/uL. Eosinophils: \>0.750\*10\^3 c/uL. Basophils: \> 400 mm\^3. Monocytes: \>2000 mm\^3. Lymphocytes: \<0.750\*10\^3 c/uL/\>7.50\*10\^3 c/uL.
| participants | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Low hemoglobin | 0 | 1 |
| Low hematocrit | 0 | 1 |
| Low erythrocytes | 0 | 0 |
| Low platelets | 0 | 0 |
| High platelets | 0 | 1 |
| Low leukocytes | 0 | 0 |
| High leukocytes | 1 | 0 |
| Low neutrophils+bands | 0 | 1 |
| Low lymphocytes | 2 | 2 |
| High lymphocytes | 0 | 0 |
| High monocytes | 0 | 0 |
| High basophils | 0 | 0 |
| High eosinophils | 0 | 0 |
ULN=upper limit of normal; BL=baseline. Marked abnormality criteria: Alkaline phosphatase: \>2\*ULN, or if BL\>ULN, use \>3\*BL; aspartate aminotransferase: \>3\*ULN, or if BL\>ULN,use \>4\*BL; alanine aminotransferase: \>3\*ULN, or if BL\>ULN, use \>4\*BL; G-Glutamyl transferase: \>2\*ULN, or if BL\>ULN, use \>3\*BL; Bilirubin: \>2\*ULN, or if BL\>ULN, use \>4\*BL; blood urea nitrogen: \>2\*BL; creatinine: \>1.5\*BL.
| participants | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| High alkaline phosphatase | 0 | 0 |
| High aspartate aminotransferase | 0 | 0 |
| High alanine aminotransferase | 0 | 0 |
| High G-Glutamyl transferase | 0 | 0 |
| High bilirubin | 0 | 0 |
| High blood urea nitrogen | 0 | 0 |
| High creatinine | 1 | 0 |
LLN=lower limit of normal; ULN=upper limit of normal; BL=baseline. Marked abnormality: Sodium: \<0.95\*LLN/\>1.05\*ULN,or if BL\<LLN, use 0.95\*BL or \>ULN,or if BL\>ULN, use\>1.05\*BL or \<LLN. Potassium: \<0.9\*LLN/\>1.1\* ULN,or if BL\<LLN, use 0.9\*BL or \>ULN, or if BL\>ULN, use\>1.1\*BL or \<LLN. Chloride: \<0.9\*LLN/\>1.1\*ULN, or if BL\<LLN, use 0.9\*BL or \>ULN, or if BL\>ULN, use\>1.1\*BL or \<LLN. Calcium: \<0.8\*LLN/\>1.2\*ULN, or if BL\<LLN, use 0.75\*BL or \>ULN, or if BL\>ULN, use\>1.25\*BL or \<LLN. Phosphorous: \<0.75\*LLN/\>1.25\*ULN, or if BL\<LLN, use 0.67\*BL or \>ULN, or if BL\>ULN, use\>1.33\*BL or \<LLN.
| participants | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Low sodium | 0 | 0 |
| High sodium | 0 | 0 |
| Low potassium | 0 | 0 |
| High potassium | 1 | 0 |
| Low chloride | 0 | 0 |
| High chloride | 0 | 0 |
| Low calcium | 0 | 0 |
| High calcium | 0 | 0 |
| Low phosphorous | 0 | 0 |
| High phosphorous | 0 | 0 |
LLN=lower limit of normal; ULN=upper limit of normal; BL-baseline. Marked abnormality c: serum glucose:\<65 mg/dL/\>220 mg/dL; fasting serum glucose: \<0.8\* LLN/\>1.5\* ULN, or if BL\<LLN, use 0.8\*BL or \>ULN, or if BL\>ULN, use \>2.0\*BL or \<LLN; total protein: \<0.9\*LLN/\>1.1\* ULN; albumin: \<0.9\*LLN,or if BL\<LLN, use \<0.75 BL; uric acid: \>1.5\* ULN, or if BL\>ULN, use \>2\*BL. Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, red blood cells, white blood cells):Use ≥2 when BL value missing or value ≥4,or when predose=0 or 0.5. Use ≥3 when predose=1. Use ≥4 when predose=2 or 3
| participants | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Low serum glucose (n=27, n=23) | 1 | 0 |
| High serum glucose (n=27, n=23) | 1 | 1 |
| Low fasting glucose (n=20, n=17) | 0 | 0 |
| High fasting glucose (n=20, n=17) | 1 | 0 |
| Low total protein (n=27, n=23) | 0 | 0 |
| High total protein (n=27, n=23) | 0 | 0 |
| Low albumin (n=27, n=23) | 0 | 0 |
| High uric acid (n=27, n=23) | 0 | 0 |
| High urine protein (n=27, n=23) | 1 | 1 |
| High urine glucose (n=27, n=23) | 0 | 0 |
| High urine blood (n=27, n=23) | 2 | 1 |
| High leukocyte esterase (n=27, n=23) | 4 | 4 |
| High urine white blood cells (n=10, n=9) | 2 | 3 |
| High urine red blood cells (n=10, n=8) | 3 | 3 |
Wrist synovitis was assessed by postgadolinium MRI enhancement according to OMERACT 6 RAMRIS in 3 wrist regions: distal radioulnar, radiocarpal, and intercarpal and carpometacarpal joints. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3\*3 wrist regions), indicating most severe damage. Change in synovitis score=Follow-up synovitis score-baseline synovitis score.
| units on a scale | Abatacept + Methotrexate | Placebo (PLA) + MTX |
|---|---|---|
| Double-blind Period: Mean Change From Baseline in OMERACT 6 Wrist Synovitis Score: Post Hoc Sensitivity Analysis Using Parametric ANCOVA Analysis | -0.31 ± 0.26 | 0.38 ± 0.27 |
Vital signs, which included blood pressure, heart rate, respiration, and temperature, were monitored predose and 1 hour after start of infusion. Changes in vital signs were determined to be significantly abnormal at the discretion of the investigator but were generally those that either exceeded, or failed to reach, normal parameters. Normal vital sign parameter ranges varied by site.
| participants | Abatacept + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Double-blind Period:Number of Participants With Significantly Abnormal Changes in Vital Signs | 0 | 0 |
On-Rx=on treatment; post-Rx=post treatment. ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction Category=reactivity against constant regions and/or hinge region of human IgG1.
| participants | Abatacept + Methotrexate |
|---|---|
| Overall on-Rx visits, CTLA4 + possibly Ig (n=27) | 0 |
| Overall on-Rx visits, Ig and/or junction (n=27) | 0 |
| Overall post-Rx visits, CTLA4 + possibly Ig (n=1) | 0 |
| Overall post-Rx visits, Ig and/or junction (n=1) | 0 |
| Overall visits, CTLA4 + possibly Ig (n=27) | 0 |
| Overall visits, Ig and/or junction (n=27) | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABA + MTX | — | 0/27 (0%) | 12/27 (44.4%) |
| PLA + MTX | — | 2/23 (8.7%) | 8/23 (34.8%) |
| Event | ABA + MTX | PLA + MTX |
|---|---|---|
| ATRIAL FIBRILLATIONCardiac disorders | 0/27 | 1/23 |
| OVERDOSEInjury, poisoning and procedural complications | 0/27 | 1/23 |
| Event | ABA + MTX | PLA + MTX |
|---|---|---|
| NAUSEAGastrointestinal disorders | 4/27 | 0/23 |
| BACK PAINMusculoskeletal and connective tissue disorders | 3/27 | 0/23 |
| FLUSHINGVascular disorders | 0/27 | 2/23 |
| HEADACHENervous system disorders | 1/27 | 2/23 |
| NASOPHARYNGITISInfections and infestations | 1/27 | 2/23 |
| EPISTAXISRespiratory, thoracic and mediastinal disorders | 0/27 | 2/23 |
| DIZZINESSNervous system disorders | 2/27 | 0/23 |
| DIARRHOEAGastrointestinal disorders | 2/27 | 1/23 |
| SINUSITISInfections and infestations | 2/27 | 0/23 |
| COUGHRespiratory, thoracic and mediastinal disorders | 2/27 | 1/23 |
| Age Continuous(years) | Abatacept (ABA) + Methotrexate (MTX) | Placebo (PLA) + MTX | Total |
|---|---|---|---|
| Mean | 51.7 ± 11.2 | 52.5 ± 11.5 | 52.1 ± 11.2 |
| Sex: Female, Male(Participants) | Abatacept (ABA) + Methotrexate (MTX) | Placebo (PLA) + MTX | Total |
|---|---|---|---|
| Female | 16 | 16 | 32 |
| Male | 11 | 7 | 18 |
| Region of Enrollment(participants) | Abatacept (ABA) + Methotrexate (MTX) | Placebo (PLA) + MTX | Total |
|---|---|---|---|
| Belgium | 9 | 7 | 16 |
| Germany | 10 | 6 | 16 |
| Netherlands | 3 | 4 | 7 |
| Spain | 2 | 2 | 4 |
| Sweden | 2 | 3 | 5 |
| United Kingdom | 1 | 1 | 2 |
| Rheumatoid Factor (RF) Status(participants) | Abatacept (ABA) + Methotrexate (MTX) | Placebo (PLA) + MTX | Total |
|---|---|---|---|
| Negative | 12 | 4 | 16 |
| Positive | 15 | 19 | 34 |
| Anti-CCP2 Status(participants) | Abatacept (ABA) + Methotrexate (MTX) | Placebo (PLA) + MTX | Total |
|---|---|---|---|
| Negative | 14 | 6 | 20 |
| Positive | 13 | 17 | 30 |
| Duration of Rheumatoid Arthritis(months) | Abatacept (ABA) + Methotrexate (MTX) | Placebo (PLA) + MTX | Total |
|---|---|---|---|
| Mean | 25.7 ± 18.0 | 28.2 ± 17.0 | 26.8 ± 17.4 |
| Disease Activity Score (DAS) 28 (C-Reactive Protein [CRP])(units on a scale) | Abatacept (ABA) + Methotrexate (MTX) | Placebo (PLA) + MTX | Total |
|---|---|---|---|
| Mean | 5.3 ± 1.1 | 5.3 ± 0.9 | 5.3 ± 1.0 |
| Number of Tender Joints(joints) | Abatacept (ABA) + Methotrexate (MTX) | Placebo (PLA) + MTX | Total |
|---|---|---|---|
| Mean | 12.9 ± 7.1 | 13.3 ± 7.2 | 13.1 ± 7.2 |
2 further baseline measures are reported on the registry.
The record gives a start of May 2007, a primary completion of Aug 2009 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept